Net Debt Summary of Gene Biotherapeutics, Inc.

Gene Biotherapeutics, Inc.'s latest annual net debt in 2022 was - USD , down 0.0% from previous year.
Gene Biotherapeutics, Inc.'s latest quarterly net debt in 2022 FY was - USD , down 0.0% from previous quarter.
Gene Biotherapeutics, Inc. reported annual net debt of - USD in 2021, down -100.0% from previous year.
Gene Biotherapeutics, Inc. reported annual net debt of 874.44 Thousand USD in 2020, down -21.99% from previous year.
Gene Biotherapeutics, Inc. reported quarterly net debt of - USD for 2021 FY, down -100.0% from previous quarter.
Gene Biotherapeutics, Inc. reported quarterly net debt of 874.44 Thousand USD for 2020 FY, down -21.99% from previous quarter.

Annual Net Debt Chart of Gene Biotherapeutics, Inc. (2022 - 1995)

Historical Annual Net Debt of Gene Biotherapeutics, Inc. (2022 - 1995)

Year	Net Debt	Net Debt Growth
2022	- USD	0.0%
2021	- USD	-100.0%
2020	874.44 Thousand USD	-21.99%
2019	1.12 Million USD	13.94%
2018	983.82 Thousand USD	-16.79%
2017	1.18 Million USD	885.84%
2016	119.93 Thousand USD	-87.03%
2015	924.59 Thousand USD	96.01%
2014	471.7 Thousand USD	2197.47%
2013	-22.48 Thousand USD	99.03%
2012	-2.32 Million USD	50.69%
2011	-4.72 Million USD	28.94%
2010	-6.64 Million USD	-97.52%
2009	-3.36 Million USD	-214.65%
2008	2.93 Million USD	197.84%
2007	-2.99 Million USD	49.44%
2006	-5.93 Million USD	72.78%
2005	-21.78 Million USD	-711.09%
2004	-2.68 Million USD	38.18%
2003	-4.34 Million USD	8.88%
2002	-4.76 Million USD	-6849.91%
2001	-68.61 Thousand USD	85.96%
2000	-488.78 Thousand USD	78.53%
1999	-2.27 Million USD	47.74%
1998	-4.35 Million USD	66.9%
1997	-13.16 Million USD	-1262.11%
1996	1.13 Million USD	608.64%
1995	159.81 Thousand USD	0.0%

Year	Net Debt	Net Debt Growth
2022 FY	- USD	0.0%
2021 FY	- USD	-100.0%
2020 FY	874.44 Thousand USD	-21.99%
2020 Q1	1.21 Million USD	8.37%
2020 Q2	-96.78 Thousand USD	-107.97%
2020 Q3	554.58 Thousand USD	673.02%
2020 Q4	874.44 Thousand USD	57.67%
2019 Q4	1.12 Million USD	0.0%
2019 FY	1.12 Million USD	13.94%
2019 Q1	82.11 Thousand USD	0.0%
2018 FY	983.82 Thousand USD	-16.79%
2017 Q1	871.48 Thousand USD	626.66%
2017 FY	1.18 Million USD	885.84%
2016 FY	119.93 Thousand USD	-87.03%
2016 Q1	927.49 Thousand USD	0.31%
2016 Q2	17.15 Thousand USD	-98.15%
2016 Q3	-729.48 Thousand USD	-4352.32%
2016 Q4	119.93 Thousand USD	116.44%
2015 Q3	801.03 Thousand USD	32.84%
2015 Q4	924.59 Thousand USD	15.43%
2015 Q2	602.98 Thousand USD	6901.12%
2015 Q1	-8866.00 USD	-101.88%
2015 FY	924.59 Thousand USD	96.01%
2014 FY	471.7 Thousand USD	2197.47%
2014 Q1	253.99 Thousand USD	1229.41%
2014 Q2	-719.22 Thousand USD	-383.17%
2014 Q3	-71.64 Thousand USD	90.04%
2014 Q4	471.7 Thousand USD	758.4%
2013 Q1	-365.02 Thousand USD	84.32%
2013 FY	-22.48 Thousand USD	99.03%
2013 Q4	-22.48 Thousand USD	96.16%
2013 Q3	-585.2 Thousand USD	11.14%
2013 Q2	-658.55 Thousand USD	-80.42%
2012 Q4	-2.32 Million USD	47.94%
2012 Q3	-4.47 Million USD	28.69%
2012 Q2	-6.27 Million USD	30.86%
2012 Q1	-9.07 Million USD	-92.12%
2012 FY	-2.32 Million USD	50.69%
2011 Q1	-4.93 Million USD	25.73%
2011 Q4	-4.72 Million USD	-109.08%
2011 Q3	-2.25 Million USD	29.06%
2011 Q2	-3.18 Million USD	35.49%
2011 FY	-4.72 Million USD	28.94%
2010 Q3	-7.7 Million USD	22.42%
2010 FY	-6.64 Million USD	-97.52%
2010 Q2	-9.92 Million USD	16.0%
2010 Q1	-11.81 Million USD	-251.27%
2010 Q4	-6.64 Million USD	13.72%
2009 Q1	5.76 Million USD	96.33%
2009 Q2	8.58 Million USD	49.03%
2009 Q3	-783.24 Thousand USD	-109.12%
2009 FY	-3.36 Million USD	-214.65%
2009 Q4	-3.36 Million USD	-329.45%
2008 Q4	2.93 Million USD	2417.9%
2008 Q1	-1.93 Million USD	35.5%
2008 Q3	-126.57 Thousand USD	87.98%
2008 FY	2.93 Million USD	197.84%
2008 Q2	-1.05 Million USD	45.55%
2007 Q1	-19.77 Million USD	-233.45%
2007 Q4	-2.99 Million USD	67.6%
2007 Q2	-15.04 Million USD	23.93%
2007 Q3	-9.25 Million USD	38.49%
2007 FY	-2.99 Million USD	49.44%
2006 Q3	-11.52 Million USD	29.35%
2006 Q4	-5.93 Million USD	48.54%
2006 Q1	-19.37 Million USD	0.0%
2006 Q2	-16.31 Million USD	15.79%
2006 FY	-5.93 Million USD	72.78%
2005 Q3	-2.51 Million USD	2.03%
2005 Q2	-2.56 Million USD	1.03%
2005 FY	-21.78 Million USD	-711.09%
2005 Q1	-2.59 Million USD	1.14%
2004 Q4	-2.62 Million USD	2.39%
2004 Q3	-2.68 Million USD	2.34%
2004 Q2	-2.75 Million USD	2.6%
2004 Q1	-2.82 Million USD	3.14%
2004 FY	-2.68 Million USD	38.18%
2003 FY	-4.34 Million USD	8.88%
2003 Q4	-2.91 Million USD	32.91%
2003 Q3	-4.34 Million USD	2.66%
2003 Q2	-4.46 Million USD	2.28%
2003 Q1	-4.56 Million USD	1.73%
2002 Q4	-4.64 Million USD	2.52%
2002 FY	-4.76 Million USD	-6849.91%
2002 Q2	384.29 Thousand USD	22.93%
2002 Q3	-4.76 Million USD	-1340.91%
2002 Q1	312.6 Thousand USD	70.72%
2001 Q2	-172.49 Thousand USD	34.21%
2001 Q3	-68.61 Thousand USD	60.22%
2001 Q4	183.11 Thousand USD	366.86%
2001 FY	-68.61 Thousand USD	85.96%
2001 Q1	-262.2 Thousand USD	35.98%
2000 Q1	-1.58 Million USD	13.12%
2000 Q2	-352.68 Thousand USD	77.72%
2000 Q4	-409.59 Thousand USD	16.2%
2000 FY	-488.78 Thousand USD	78.53%
2000 Q3	-488.78 Thousand USD	-38.59%
1999 FY	-2.27 Million USD	47.74%
1999 Q4	-1.82 Million USD	0.0%
1998 Q1	-6.4 Million USD	15.79%
1998 Q2	-5 Million USD	21.88%
1998 Q3	-4.35 Million USD	12.88%
1998 FY	-4.35 Million USD	66.9%
1997 FY	-13.16 Million USD	-1262.11%
1997 Q1	8.1 Million USD	84.09%
1997 Q2	1.7 Million USD	-79.01%
1997 Q3	-13.16 Million USD	-874.17%
1997 Q4	-7.6 Million USD	42.25%
1996 FY	1.13 Million USD	608.64%
1996 Q4	4.4 Million USD	288.52%
1996 Q3	1.13 Million USD	0.0%
1995 FY	159.81 Thousand USD	0.0%

Peer Net Debt Comparison of Gene Biotherapeutics, Inc.

Name	Net Debt	Net Debt Difference
America Great Health	1.81 Million USD	100.0%
Evolutionary Genomics, Inc.	3.16 Million USD	100.0%
Innovation1 Biotech Inc.	179.15 Thousand USD	100.0%
Point of Care Nano-Technology, Inc.	-498.00 USD	100.0%
Vicapsys Life Sciences, Inc.	344.44 Thousand USD	100.0%

Global Stocks Search

Gene Biotherapeutics, Inc. (CRXM)

Net Debt Summary of Gene Biotherapeutics, Inc.

Annual Net Debt Chart of Gene Biotherapeutics, Inc. (2022 - 1995)

Historical Annual Net Debt of Gene Biotherapeutics, Inc. (2022 - 1995)

Peer Net Debt Comparison of Gene Biotherapeutics, Inc.